News & Updates
Filter by Specialty:
Abrocitinib effectively controls AD regardless of dosing regimen
In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Multiple biomarkers may improve prediction of suicidal behaviour during depression treatment
Combinations of serum biomarkers relating to cortisol, total cholesterol, and folate, as well as interleukin (IL)-1β and homocysteine, help improve the predictability of suicide attempt and increased suicidal severity, respectively, among individuals being treated for depression, according to a study.
Multiple biomarkers may improve prediction of suicidal behaviour during depression treatment
03 Aug 2023
High polygenic risk linked to earlier treatment initiation, escalation in glaucoma
High glaucoma polygenic risk score (PRS) shows a significant association with earlier initiation or escalation of intraocular pressure (IOP)-lowering therapy, according to a study, noting the potential usefulness of genetic risk stratification in glaucoma.
